Retrospective Review of records of eyes with Central serous chorioretinopathy (CSCR) that have been treated in the period between 2015 and 2021~After checking inclusion and exclusion criteria; we will enroll all cases that have been treated by the combination of eplerenone, intravitreal aflibercept and topical nepafenac.~Investigators collected and recorded the following data:~Age~Gender~Systemic hypertension (present or not)~Smoking (Yes / No)~Best corrected visual acuity (BCVA) (baseline, final)~Central macular thickness (CMT) (baseline, final)~Serous detachment Height (SDH) (baseline, final)~Duration of Follow-up ( in months)
describing the influence of; combined Eplerenone, intravitreal Aflibercept, and topical Nepafenac; on serous foveal detachment in eyes with CSCR